

FibroScan® Mini+ 430

The mobile non-invasive solution for liver disease management, ideal for multi-site configuration

Designed for multi-site sharing and near-patient testing. Powered by unique, patented and validated parameters LSM by VCTE™ and CAP™ for liver fibrosis and liver steatosis assessment.



NEW Guided VCTE™

The next generation VCTE™ technology

Intuitive features for faster examinations and simplified scanning¹

- Two new indicators that allow for quick identification of the optimal measurement location
- AutoScan feature which triggers 10 valid measurements through a single click
- SmartExam features are included: SmartDepth and Continuous CAP™



Stiffness indicator



CAP™ indicator

Smartly adaptable to all settings

- Light and easy to handle (11 lbs./5 kg) with 12.1 inch touch screen
- Battery-powered device
- Two probe connectors to easily switch between probes during exam

Adapted to all patient morphologies

Probes S+, M+ and XL+



Transport suitcase

Airplane-compatible



Enhance your FibroScan® experience with the **Liver Health Management platform**: an innovative cloud-based solution to streamline your workflow



Winner of the **Red Dot Design Award** for innovative and ergonomic design

What makes FibroScan® unique?

- A painless exam that can be performed in **less than 4 minutes** with immediate results at the point-of-care.¹
- Can be performed by **any trained operator** (physician, nurse, or medical assistant).
- Standardized examination with exceptional precision and reproducibility that can be utilized in **99% of patients**.²
- An **ecosystem of solutions** developed by Echosens to support clinical decisions for physicians: Liver Health Management platform, Scores by Echosens^{3,4}, Interpretation Guide, myFibroScan, FibroScan® Gateway and educational support.



Renowned Publication Presence & Endorsement in Clinical Practice Guidelines

4,200+ peer-reviewed publications

180+ international guidelines

More than 4,200 peer-reviewed publications and 180 international guidelines advocate the use of FibroScan® as the reference non-invasive solution for liver fibrosis, cirrhosis, and steatosis assessment across all etiologies of chronic liver disease (viral hepatitis, MASLD/MASH, alcoholic liver disease).^{5,6,7}

AASLD

ADA

AHA

APASL

EASL

AACE


AGA

AISF

Baveno VII

NICE Guidance

Examinations with FibroScan® can inform treatment decisions across the spectrum of disease



Interested in FibroScan® Mini+ 430 for your practice?
Contact us on echosens.com

LSM: Liver Stiffness Measurement / VCTE™: Vibration Controlled Transient Elastography / CAP™: Controlled Attenuation Parameter / MASLD: Metabolic dysfunction-associated steatotic liver disease (formerly known as NAFLD) / MASH: Metabolic dysfunction-associated steatohepatitis (formerly known as NASH) / LHM: Liver Health Management

References

1. Based on internal data. E431R020.1. 2. Myers, Robert P et al. "Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients." *Hepatology* (Baltimore, Md.) vol. 55,1 (2012): 199-208. doi:10.1002/hep.24624. 3. Newsome, Philip N et al. "FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study." *The Lancet. Gastroenterology & hepatology* vol. 5,4 (2020): 362-373. doi:10.1016/S2468-1253(19)30383. 4. Sanyal, Arun J et al. "Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores." *Journal of hepatology* vol. 78,2 (2023): 247-259. doi:10.1016/j.jhep.2022.10.034. 5. Baveno VII – R. de Franchis et al. *Renewing consensus in portal hypertension.* *Journal of hepatology* vol. 76,4 (2022): 959-974. doi:10.1016/j.jhep.2021.12.022. 6. European Association for the Study of the Liver. *Electronic address: easloffice@easloffice.eu et al. "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update."* *Journal of hepatology* vol. 75,3 (2021): 659-689. 7. Kanwal, Fasiha et al. "Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease." *Gastroenterology* vol. 161,5 (2021): 1657-1669.

FibroScan® Mini+ 430 or FibroScan® Mini 430, product name may vary depending on country. Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459) and are manufactured by Echosens™. These devices are designed for use in a medical practice in order to measure liver stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. This marketing material is not intended for US audience. © 2024 Echosens - Echosens™ and FibroScan® are trademarks owned by Echosens SA. All rights reserved. One-pager FibroScan® Mini+ 430 – v1 ROW – 12/2023.

